Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor)
in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Contenuto disponibile solo in lingua inglese